RADCOM Reports Record Revenues and Optimistic 2024 Outlookby Mark Eisenberg 08.08.2024RADCOM Limited records a 20% revenue increase for Q2 2024, with positive cash flow. Raises 2024 guidance amid robust 5G ...
Rockwell Automation Targets Cost Savings Amid Slower Order Growthby Mark Eisenberg 08.08.2024Rockwell Automation aims to save $220M by 2025 amid slower order growth, with a focus on cost reduction and productivity.
FS KKR Capital Posts Steady Q2 Performance with $0.77 Net Investment Incomeby Mark Eisenberg 08.08.2024FS KKR Capital delivers solid Q2 2024 results with $0.77 net investment income per share and a declared Q3 distribution ...
Astec Industries Achieves $345.5M Net Sales Amid Infrastructure Boomby Mark Eisenberg 08.08.2024Astec Industries reports strong Q2 performance with net sales of $345.5M, driven by high demand in Infrastructure Solutions segment.
Ethereum Network Activity Hits Five-Month Low Amid Market Downturnby John Darbie 08.08.2024Ethereum's transaction volume falls to a five-month low as market sentiment sours, with layer 2 solutions gaining traction.
Disney and Super Micro Stocks Drop After Earnings Missby Mark Eisenberg 08.08.2024Disney and Super Micro's earnings failed investor expectations, causing stock drops. Warner Bros. Discovery's results are awaited.
Dogecoin Faces Major Challenge from Emerging Rival Mpeppeby John Darbie 07.08.2024Dogecoin struggles as new contender Mpeppe (MPEPE) gains traction with potential 1000x returns. Explore their recent performance and future prospects.
Constellation Energy Boosts Earnings Guidance, Confident in Buybacksby Mark Eisenberg 07.08.2024Constellation Energy raises full-year earnings guidance and continues robust share buyback program, marking strong financial performance.
Jack in the Box Reports Q3 2024 Earnings Amid Sales Declineby Mark Eisenberg 07.08.2024Jack in the Box Q3 2024 earnings show a 2.2% sales decline. Company plans include digital growth and new Chicago ...
Supernus Pharmaceuticals Reports Strong Q2 2024 Growthby Mark Eisenberg 07.08.2024Supernus Pharmaceuticals sees a 24% YoY revenue increase in Q2 2024, driven by key drugs Qelbree and GOCOVRI.